Neurology
RSSArticles
-
Weight loss without cardiac side effects
A new weight-loss medication may soon be available in the United States. Arena pharmaceuticals has filed a new drug application with the FDA for lorcaserin, a selective serotonin 2C-receptor agonist, and will likely get a formal review this fall. -
Advisory panel votes against Qnexa
-
Mixed vote on rosiglitazone
-
Breast cancer indication for bevacizumab
-
No increase in seizures with DTaP vaccine
-
New REMS for quinine
-
Pharmacology Watch - Full September 2010 Issue in PDF
-
Abstract & Commentary: Is a Central Venous Blood Gas a Useful Surrogate for an Arterial Blood Gas?
The authors set out to compare arterial and central venous blood gases (ABG and VBG, respectively), to evaluate the utility and accuracy of a predefined algorithm for adjusting VBG pH and pCO2 to approximate that of ABG, and to define clinical scenarios where a VBG may not be a useful substitute for an ABG. -
Abstract & Commentary: Endotracheal Tube Size Affects Weaning Predictors
In this secondary analysis of data from a study on the pre-extubation prediction of post-extubation work of breathing in patients recovering from acute respiratory failure, Mehta and colleagues sought to determine whether the size of a patient's endotracheal tube (ETT) affected respiratory rate, tidal volume, and other "weaning parameters" commonly measured during spontaneous breathing and used to predict successful extubation. -
Clinical Briefs in Primary Care supplement